Select Page

M-Power Detroit: Community Workshop

Know the risks and symptoms of multiple myeloma, the most common blood cancer in African Americans, and how to get the best care.

 

with support from:
 AbbVie, Amgen, Binding Site, Bristol Myers Squibb, GSK, Genentech, Janssen, Karyopharm Therapeutics, and Sanofi

The M-POWER project is partnering with cities across the country to turn the core vision of the IMF Diversity Initiative into a reality: improving the short- and long-term outcomes of African-American patients with multiple myeloma.

Multiple myeloma is the most common blood cancer in African Americans, who have a greater-than-average risk of developing the disease. But when barriers to early diagnosis and treatment are removed, African-American myeloma patients do just as well, or even better than, white individuals.

M-POWER is empowering health-care professionals, community leaders, neighborhoods and families to break down those barriers by raising myeloma awareness.

%

of all cases of myeloma are in African Americans

more common in African Americans

%

of all newly diagnosed myeloma patients will be African American

Multiple Myeloma

Did you know that myeloma is the most common blood cancer in people of African descent? But doctors do not typically check people for myeloma during a regular visit because currently there are no national screening recommendations for myeloma.

That’s why it’s important to learn the early symptoms of myeloma and let your doctor know that you—or a friend or family member—are at added risk for the disease.

Because even though myeloma affects African Americans at greater rates, with early diagnosis and treatment, African Americans can have better overall survival in living with the disease.

Myeloma Tool Kit